| 1 |
Statins and risk of decompensation in hepatitis B virus-related and hepatitis C virus-related cirrhosis: Methodological issues |
|
| | Chun-Yu Lin | | | Hepatology. 2018; | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice |
|
| | Hyunah Kim,Hyeseon Lee,Tong Min Kim,So Jung Yang,Seo Yeon Baik,Seung-Hwan Lee,Jae-Hyoung Cho,Hyunyong Lee,Hyeon Woo Yim,In Young Choi,Kun-Ho Yoon,Hun-Sung Kim | | | Cardiovascular Therapeutics. 2018; : e12324 | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
Novel treatment options for portal hypertension |
|
| | Philipp Schwabl,Wim Laleman | | | Gastroenterology Report. 2017; | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Statin use is not associated with liver related mortality |
|
| | Zahra Younoszai,Li Zheng,Maria Stepanova,Madeline Erario,Rebecca Cable,Zobair M. Younossi | | | Annals of Hepatology. 2014; 13(1): 84 | | | [Pubmed] [Google Scholar] [DOI] | |
|
